Recent data published by the UK’s independent medicines regulator assures the Pfizer/BioNTech and the Oxford University/AstraZeneca vaccines meet strict regulatory standards for safety
Israel has agreed to give the first 5,000 vaccine doses to Palestinian medical workers - but only if they live in annexed east Jerusalem, while the West Bank and Gaza remain without vaccines.
AstraZeneca dose efficiency holds at 76% in the three-month period between the first and second dose - suggesting that this time period is good for maximising protection.
The vaccine roll out gives hope of a return to some form of normality, but current high COVID-19 infection numbers put the success of vaccination programmes at risk. Professor Martin Michaelis and Dr Mark Wass of University of Kent’s School of Biosciences explain why.
A new study by the University of California, Davis has found that a third of Americans are either unlikely or hesitant to get a COVID-19 vaccine when it becomes available.
New clinical trial data shows that the Johnson & Johnson vaccine is able to give 66% protection against COVID in one dose - with an 85% efficiency at the standard double-dose.
Phase Three data from the UK trial shows that Novavax still works powerfully against the UK mutation, with a less intense impact on the South African mutation at 60%.
